Adjuvant systemic therapy for primary breast cancer (Q33779184)

29 July 2017

1 reference

title

Adjuvant systemic therapy for primary breast cancer (English)

1 reference

29 July 2017

1 reference

Esteva FJ

1

1 reference

29 July 2017

Hortobagyi GN

series ordinal

2

1 reference

29 July 2017

publication date

1 October 1999

1 reference

Surgical Clinics of North America

29 July 2017

published in

1 reference

29 July 2017

volume

79

1 reference

29 July 2017

issue

5

1 reference

29 July 2017

page(s)

1075-1090

1 reference

Response to endocrine manipulation and oestrogen receptor concentration in large operable primary breast cancer

29 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2805%2970062-1

7 January 2021

neu/erbB-2 amplification identifies a poor-prognosis group of women with node-negative breast cancer. Toronto Breast Cancer Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2805%2970062-1

7 January 2021

High-dose chemotherapy with autologous hematopoietic stem-cell support for breast cancer in North America

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2805%2970062-1

7 January 2021

Quality of life assessment in patients receiving adjuvant therapy for breast cancer: the IBCSG approach. The International Breast Cancer Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2805%2970062-1

7 January 2021

Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer: the results of 20 years of follow-up

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2805%2970062-1

7 January 2021

Ten-year experience with CMF-based adjuvant chemotherapy in resectable breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2805%2970062-1

7 January 2021

Primary chemotherapy to avoid mastectomy in tumors with diameters of three centimeters or more

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2805%2970062-1

7 January 2021

Adjuvant chemotherapy with fluorouracil, doxorubicin, and cyclophosphamide, with or without Bacillus Calmette-Guerin and with or without irradiation in operable breast cancer a prospective randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2805%2970062-1

7 January 2021

Adjuvant therapy with escalating doses of doxorubicin and cyclophosphamide with or without leukocyte alpha-interferon for stage II or III breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2805%2970062-1

7 January 2021

Outcome of extensive evaluation before adjuvant therapy in women with breast cancer and 10 or more positive axillary lymph nodes

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2805%2970062-1

7 January 2021

Risk of leukemia after chemotherapy and radiation treatment for breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2805%2970062-1

7 January 2021

Complete axillary lymph node dissection for stage I-II carcinoma of the breast

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2805%2970062-1

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2805%2970062-1

7 January 2021

Reduction in new metastases in breast cancer with adjuvant clodronate treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2805%2970062-1

7 January 2021

Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2805%2970062-1

7 January 2021

bcl-2, p53, and response to tamoxifen in estrogen receptor-positive metastatic breast cancer: a Southwest Oncology Group study

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2805%2970062-1

7 January 2021

Clinical prognostic and predictive factors for primary chemotherapy in operable breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2805%2970062-1

7 January 2021

Preoperative chemotherapy induces apoptosis in early breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2805%2970062-1

7 January 2021

Status of adjuvant therapy: results of The National Surgical Adjuvant Breast Project studies on oophorectomy, postoperative radiation therapy, and chemotherapy. Other comments concerning clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2805%2970062-1

7 January 2021

Increased intensification and total dose of cyclophosphamide in a doxorubicin-cyclophosphamide regimen for the treatment of primary breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-22

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2805%2970062-1

7 January 2021

Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2805%2970062-1

7 January 2021

Two months of doxorubicin-cyclophosphamide with and without interval reinduction therapy compared with 6 months of cyclophosphamide, methotrexate, and fluorouracil in positive-node breast cancer patients with tamoxifen-nonresponsive tumors: results

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2805%2970062-1

7 January 2021

Effect of preoperative chemotherapy on the outcome of women with operable breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2805%2970062-1

7 January 2021

Tamoxifen and chemotherapy for lymph node-negative, estrogen receptor-positive breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2805%2970062-1

7 January 2021

Eight-year results of a randomized clinical trial comparing total mastectomy and lumpectomy with or without irradiation in the treatment of breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2805%2970062-1

7 January 2021

Patient selection in high-dose chemotherapy trials: relevance in high-risk breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2805%2970062-1

7 January 2021

Efficacy, toxicity, and applicability of high-dose sequential chemotherapy as adjuvant treatment in operable breast cancer with 10 or more involved axillary nodes: five-year results

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2805%2970062-1

7 January 2021

Meeting highlights: International Consensus Panel on the Treatment of Primary Breast Cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2805%2970062-1

7 January 2021

Meeting Highlights: International Consensus Panel on the Treatment of Primary Breast Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2805%2970062-1

7 January 2021

Prognostic importance of c-erbB-2 expression in breast cancer. International (Ludwig) Breast Cancer Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2805%2970062-1

7 January 2021

Prognostic value of bcl-2 expression in invasive breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2805%2970062-1

7 January 2021

Current status of adjuvant systemic therapy for primary breast cancer: progress and controversy

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2805%2970062-1

7 January 2021

Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. Protocol 19 Aredia Breast Cancer Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2805%2970062-1

7 January 2021

Analysis of dose intensity for adjuvant chemotherapy trials in stage II breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2805%2970062-1

7 January 2021

Duration and reintroduction of adjuvant chemotherapy for node-positive premenopausal breast cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2805%2970062-1

7 January 2021

Neoadjuvant chemotherapy in the conservative management of breast cancer: a study of 252 patients

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2805%2970062-1

7 January 2021

Apoptosis. Its significance in cancer and cancer therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2805%2970062-1

7 January 2021

Cancer statistics, 1998.

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2805%2970062-1

7 January 2021

The development of biological therapies for breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2805%2970062-1

7 January 2021

Ovarian function and adjuvant chemotherapy for early breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2805%2970062-1

7 January 2021

High-dose chemotherapy and autologous bone marrow support as consolidation after standard-dose adjuvant therapy for high-risk primary breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2805%2970062-1

7 January 2021

Oral clodronate and reduction in loss of bone mineral density in women with operable primary breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2805%2970062-1

7 January 2021

Natural history of node-negative breast cancer: a study of 826 patients with long-term follow-up

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2805%2970062-1

7 January 2021

The sequencing of chemotherapy and radiation therapy after conservative surgery for early-stage breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2805%2970062-1

7 January 2021

Pathological prognostic factors in stage I (T1N0M0) and stage II (T1N1M0) breast carcinoma: a study of 644 patients with median follow-up of 18 years

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2805%2970062-1

7 January 2021

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2805%2970062-1

7 January 2021

Multicenter randomized clinical trial of goserelin versus surgical ovariectomy in premenopausal patients with receptor-positive metastatic breast cancer: an intergroup study

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2805%2970062-1

7 January 2021

erbB-2, p53, and efficacy of adjuvant therapy in lymph node-positive breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2805%2970062-1

7 January 2021

The natural history of breast cancer with more than 10 positive nodes

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2805%2970062-1

7 January 2021

Cancer incidence and mortality, 1973-1995: a report card for the U.S.

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2805%2970062-1

7 January 2021

Dose and dose intensity of adjuvant chemotherapy for stage II, node-positive breast carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2805%2970062-1

7 January 2021

HER-2/neu protein: a target for antigen-specific immunotherapy of human cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2805%2970062-1

7 January 2021

10.1016/S0039-6109(05)70062-1

Identifiers

DOI

1 reference

29 July 2017

1 reference